The Cardiovascular Research Foundation (CRF) has release details of the 12 late-breaking trials and 16 first report investigations that are to be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2017 scientific symposium (29 October–2 November, Denver, USA).
Both the late-breaking clinical trials and first report investigations will be presented in the main arena (see the agenda for full details). They are as follows:
30 October (Monday)
Late-breaking trials
- CULPRIT-SHOCK: A randomised Trial of multivessel PCI in cardiogenic shock
- EXCEL QOL: Quality of life after PCI vs CABG in left main coronary artery disease
- DKCRUSH-V: A randomised trial of double kissing crush vs provisional stenting for treatment of distal left main bifurcation lesions
First report investigations
- HREVS: A randomised trial of PCI vs CABG vs hybrid revascularization in patients with coronary artery disease
- HARMONEE: A randomised trial of a bioabsorbable polymer-based DES with a luminal CD34+ antibody coating vs a durable polymer-based DES in patients with coronary artery disease
- DARE: A randomised trial of a drug-eluting balloon vs a metallic DES in patients with coronary artery in-stent restenosis
- VAMPIRE 3: A randomised trial of distal filter protection during PCI of high-risk plaque
31 October (Tuesday)
Late-breaking trials
- ABSORB IV: 30-day outcomes from a randomised trial of a bioresorbable scaffold vs a metallic DES in patients with coronary artery disease
- ABSORB III: 3-year outcomes from a randomised trial of a bioresorbable scaffold vs a metallic DES in patients with coronary artery disease
- PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in intermediate-risk patients with aortic stenosis
First report investigations
- ABSORB II: 4-year outcomes from a randomised trial of a bioresorbable scaffold vs a metallic DES in patients with coronary artery disease
- CrossBoss First: A randomised trial of antegrade dissection and re-entry vs standard wire escalation for crossing coronary artery chronic total occlusions
- REVASC: A randomised trial to assess recovery of left ventricular function after PCI of coronary artery chronic total occlusions
- FAVOR II China: Diagnostic accuracy of the angiographic quantitative flow ratio in patients with coronary artery disease
- FAVOR II Europe Japan: Diagnostic accuracy of the angiographic quantitative flow ratio in patients with coronary artery disease
1 November (Wednesday)
Late-breaking trials
- SENIOR: A randomised trial of a bioabsorbable polymer-based Metallic DES vs a BMS with short DAPT in patients with coronary artery disease older than 75 years
- DAPT STEMI: A randomised trial of 6-month vs 12-month DAPT after DES implantation in STEMI
- REDUCE: A randomised trial of 3-month vs 12-month DAPT after implantation of a bioabsorbable polymer-based metallic DES with a luminal CD34+ antibody coating in patients with ACS
First report investigations
- MITRAL: 30-day outcomes of transcatheter MV replacement in patients with severe mitral valve disease secondary to mitral annular calcification or failed annuloplasty rings
- INTREPID: 30-day outcomes of transcatheter MV replacement in patients with severe mitral regurgitation
- TENDYNE: 1-year outcomes of transcatheter MV replacement in patients with severe mitral regurgitation
- TRACER: 6-month outcomes of transcatheter MV Neochordal repair in patients with severe primary mitral regurgitation
- MAVERIC: 6-month outcomes of transcatheter MV repair in patients with severe secondary mitral regurgitation
2 November (Thursday)
Late-breaking trials
- PREVAIL: 5-year outcomes from a randomised trial of left atrial appendage closure vs medical therapy in patients with non-valvular atrial fibrillation
- ORBITA: A randomised, sham-controlled trial of PCI in patients with coronary artery disease
- FAME 2: 3-year clinical and cost-effectiveness outcomes of FFR-guided PCI in patients with coronary artery disease
First report investigations
- TRI-REPAIR: 30-day outcomes of transcatheter TV repair in patients with severe secondary tricuspid regurgitation
- FORMA: 30-day outcomes of transcatheter TV repair in patients with severe secondary tricuspid regurgitation
